Banc of America Cuts Trimeris to 'Neutral'

Analyst Michael King sees little hope for near-term sales acceleration for the drug maker's HIV drug

Banc of America downgraded Trimeris (TRMS ) to neutral from buy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.